I agree that this site is using cookies. You can find further informations here.
X
Hortobagyi, G.N.
762  results:
Search for persons X
?
1

113MO NATALEE update: Safety and treatment (tx) duration of..:

Barrios, C.H. ; Harbeck, N. ; Hortobagyi, G.N....
ESMO Open.  9 (2024)  - p. 103101 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Corrigendum to "Tucatinib versus placebo added to trastuzum..:

Curigliano, G. ; Mueller, V. ; Borges, V....
Annals of Oncology.  34 (2023)  7 - p. 630 , 2023
Link: https://doi.org/10.1016/..
 
?
3

Tucatinib versus placebo added to trastuzumab and capecitab..:

Curigliano, G. ; Mueller, V. ; Borges, V....
Annals of Oncology.  33 (2022)  3 - p. 321-329 , 2022
Link: https://doi.org/10.1016/..
 
?
4

Updated results from MONALEESA-2, a phase III trial of firs..:

Hortobagyi, G.N. ; Stemmer, S.M. ; Burris, H.A....
Annals of Oncology.  30 (2019)  11 - p. 1842 , 2019
Link: https://doi.org/10.1093/..
 
?
5

Breast cancer-specific survival (BCSS) in patients (pts) wi..:

Winer, E.P. ; Shak, S. ; Sledge Jr., G.W....
The Breast.  44 (2019)  - p. S100-S101 , 2019
Link: https://doi.org/10.1016/..
 
?
6

Updated results from MONALEESA-2, a phase III trial of firs..:

Hortobagyi, G.N. ; Stemmer, S.M. ; Burris, H.A....
Annals of Oncology.  29 (2018)  7 - p. 1541-1547 , 2018
Link: https://doi.org/10.1093/..
 
?
7

Long-term survival outcomes of triple-receptor negative bre..:

Reddy, S M ; Barcenas, C H ; Sinha, A K...
British Journal of Cancer.  118 (2017)  1 - p. 17-23 , 2017
Link: https://doi.org/10.1038/..
 
?
8

EZH2 contributes to the response to PARP inhibitors through..:

Yamaguchi, H ; Du, Y ; Nakai, K...
Oncogene.  37 (2017)  2 - p. 208-217 , 2017
Link: https://doi.org/10.1038/..
 
?
9

The 21-Gene Recurrence Score and Locoregional Recurrence Ra..:

Woodward, W.A. ; Barlow, W.E. ; Jagsi, R....
International Journal of Radiation Oncology*Biology*Physics.  96 (2016)  2 - p. S146 , 2016
Link: https://doi.org/10.1016/..
 
?
10

Clinicopathological and surgical factors associated with lo..:

Harano, K. ; Lei, X. ; Gonzalez-Angulo, A. M....
Breast Cancer Research and Treatment.  159 (2016)  2 - p. 367-374 , 2016
Link: https://doi.org/10.1007/..
 
?
11

Ribociclib + letrozole for first-line treatment of HR+, HER..:

André, F. ; Stemmer, S.M. ; Hortobagyi, G.N....
European Journal of Cancer.  69 (2016)  - p. S7 , 2016
Link: https://doi.org/10.1016/..
 
?
12

Meta-analysis of stomatitis in clinical studies of everolim..:

Rugo, H.S. ; Hortobagyi, G.N. ; Yao, J....
Annals of Oncology.  27 (2016)  3 - p. 519-525 , 2016
Link: https://doi.org/10.1093/..
 
?
13

SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to ..:

Nahleh, Z. A. ; Barlow, W. E. ; Hayes, D. F....
Breast Cancer Research and Treatment.  158 (2016)  3 - p. 485-495 , 2016
Link: https://doi.org/10.1007/..
 
?
14

Hypofractionated Whole Breast Irradiation Results in Less A..:

Shaitelman, S.F. ; Buchholz, T.A. ; Hunt, K.K....
International Journal of Radiation Oncology*Biology*Physics.  90 (2014)  5 - p. 1264 , 2014
Link: https://doi.org/10.1016/..
 
?
15

1LBA Everolimus plus exemestane for hormone receptor-positi..:

Piccart, M. ; Hortobagyi, G.N. ; Campone, M....
European Journal of Cancer.  50 (2014)  - p. S1 , 2014
Link: https://doi.org/10.1016/..
 
1-15